Waldenström's macroglobulinemia: The LYSA pragmatic guidelines
Damien Roos-Weil1, Cécile Tomowiak2, Stéphanie Poulain3
1Sorbonne Université, AP-HP, Service d'Hématologie Clinique, GH Pitié-Salpêtrière, Paris, France; Centre de Recherche des Cordeliers, Sorbonne Université, Université Paris Cité, Inserm UMRS 1138, Drug Resistance in Hematological Malignancies Team, F, Paris 75006, France.
European Journal of Cancer (Oxford, England : 1990)
|December 5, 2025
Summary
Waldenström
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Waldenström's macroglobulinemia (WM) is a rare, indolent B-cell lymphoma primarily affecting older adults.
- Recent advancements have improved understanding of WM pathogenesis, biomarkers, and novel therapies.
- Traditional chemoimmunotherapy is being complemented by new treatment strategies.
Purpose of the Study:
- To provide comprehensive, evidence-based recommendations for diagnosing and treating Waldenström's macroglobulinemia.
- To outline strategies for both initial (frontline) and recurrent (relapsed) disease management.
- To equip clinicians with a practical framework for optimal patient care.
Main Methods:
- Review of latest clinical research findings.
- Expert consensus development.
- Analysis of current practice standards in WM management.
Main Results:
- Development of updated guidelines for WM diagnosis and molecular evaluation.
- Inclusion of novel therapeutic approaches alongside traditional chemoimmunotherapy.
- Strategies for managing both frontline and relapsed WM disease are detailed.
Conclusions:
- The management landscape of Waldenström's macroglobulinemia has been significantly reshaped by recent progress.
- These guidelines offer a practical framework for clinicians to deliver optimal care.
- Evidence-based recommendations aim to improve patient outcomes in WM.
